Coq10 Migraine Meta-analysis: What the Evidence Says

Quick Answer

Coq10 Migraine Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Migraine is associated with psychiatric disorders, atopic diseases, and cardiovascular disease, among others, with mutual influences among these conditions. [Wu Jianping (2025); evidence level 1]
• The high disability rate associated with migraine significantly impairs patients' quality of life (QoL) and productivity, creating significant financial strain on individuals and the community (;). [Wu Jianping (2025); evidence level 1]
• Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026); evidence level 3]
• These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization. [Santangelo Domenico (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For coq10 migraine meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Wu Jianping (2025). Oral preventive medications for migraine in adults aged 18–65: a network meta-analysis. DOI: 10.3389/fphar.2025.1620887. PMCID: PMC12443741. PMID: 40978493. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12443741/
• Santangelo Domenico (2026). Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms. DOI: 10.3390/jcm15041476. PMCID: PMC12942355. PMID: 41753160. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942355/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.